Neonatal intrahippocampal HIV-1 protein Tat1-86 injection: Neurobehavioral alterations in the absence of increased inflammatory cytokine activation

International Journal of Developmental Neuroscience

Volumn 38, Issue , 2014, Pages 195-203

  Moran, Landhing M ^a   Fitting, Sylvia ^a,b   Booze, Rosemarie M ^a   Webb, Katy M ^a,c   Mactutus, Charles F ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Developmental delay; Gp120; HIV 1; Neurotoxicity; Tat1 86

Indexed keywords

GLYCOPROTEIN GP 120; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; TAT1 86; UNCLASSIFIED DRUG; VIRUS PROTEIN; AMINO ACID TRANSPORTER; CYTOKINE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; SLC16A10 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HABITUATION; HIPPOCAMPUS; IN VIVO STUDY; LOCOMOTION; MALE; NEUROTOXICITY; NEWBORN; NONHUMAN; PREPULSE INHIBITION; RAT; REFLEX; SPRAGUE DAWLEY RAT; AGE; ANIMAL; ANIMAL EMBRYO; CHEMICALLY INDUCED; DEVELOPMENTAL DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; ORIENTATION; PATHOPHYSIOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; RIGHTING REFLEX; SENSORY GATING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AGE FACTORS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; ANIMALS, NEWBORN; CYTOKINES; DEVELOPMENTAL DISABILITIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO, MAMMALIAN; FEMALE; HIPPOCAMPUS; HIV ENVELOPE PROTEIN GP120; HUMANS; MALE; MOTOR ACTIVITY; ORIENTATION; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; REFLEX, RIGHTING; SENSORY GATING;

EID: 84908363864     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2014.09.004     Document Type: Article

References (112)

1. Aksenov M.Y., Aksenova M.V., Nath A., Ray P.D., Mactutus C.F., Booze R.M. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 2006, 27:217-228.
2. Aksenov M.Y., Aksenova M.V., Silvers J.M., Mactutus C.F., Booze R.M. Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons. Neurotoxicology 2008, 29:971-977.
3. Aksenov M.Y., Hasselrot U., Bansal A.K., Wu G., Nath A., Anderson C., Mactutus C.F., Booze R.M. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci. Lett. 2001, 305:5-8.
4. Aksenov M.Y., Hasselrot U., Wu G., Nath A., Anderson C., Mactutus C.F., Booze R.M. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res. 2003, 987:1-9.
5. Aksenova M.V., Aksenov M.Y., Mactutus C.F., Booze R.M. Cell culture models of oxidative stress and injury in the central nervous system. Curr. Neurovasc. Res. 2005, 2:73-89.
6. Aksenova M.V., Silvers J.M., Aksenov M.Y., Nath A., Ray P.D., Mactutus C.F., Booze R.M. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci. Lett. 2006, 395:235-239.
7. Arisi G.M. Nervous and immune systems signals and connections: cytokines in hippocampus physiology and pathology. Epilepsy Behav. 2014, [Epub ahead of print].
8. AVMA 2000 Report of the AVMA Panel on Euthanasia. J. Am. Vet. Med. Assoc. 2001, 218:669-696.
9. Bansal A.K., Mactutus C.F., Nath A., Maragos W., Hauser K.F., Booze R.M. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 2000, 879:42-49.
10. Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res. 2010, 339:269-280.
11. Bertrand S.J., Aksenova M.V., Mactutus C.F., Booze R.M. HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp. Neurol. 2013, 248:228-235.
12. Bertrand S.J., Mactutus C.F., Aksenova M.V., Espensen-Sturges T.D., Booze R.M. Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens. J. Neurochem. 2014, 128:140-151.
13. Bilbo S.D., Schwarz J.M. The immune system and developmental programming of brain and behavior. Frontiers Neuroendocrin. 2012, 33:267-286.
14. Brenneman D.E., Westbrook G.L., Fitzgerald S.P., Ennist D.L., Elkins K.L., Ruff M.R., Pert C.B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988, 335:639-642.
15. Bruce-Keller A.J., Chauhan A., Dimayuga F.O., Gee J., Keller J.N., Nath A. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J. Neurosci. 2003, 23:8417-8422.
16. Campbell G.R., Loret E.P. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?. Retrovirology 2009, 6:50.
17. Cassol E., Misra V., Morgello S., Gabuzda D. Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J. Neuroimmune Pharmacol. 2013, 8:1087-1097.
18. Catani M.V., Corasaniti M.T., Ranalli M., Amantea D., Litovchick A., Lapidot A., Melino G. The Tat antagonist neomycin B hexa-arginine conjugate inhibits gp-120-induced death of human neuroblastoma cells. J. Neurochem. 2003, 84:1237-1245.
19. Chang L., Wang G.J., Volkow N.D., Ernst T., Telang F., Logan J., Fowler J.S. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 2008, 42:869-878.
20. Chefer V.I., Zakharova I., Shippenberg T.S. Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions. J. Neurosci. 2003, 23:3076-3084.
21. Cheng J., Nath A., Knudsen B., Hochman S., Geiger J.D., Ma M., Magnuson D.S. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 1998, 82:97-106.
22. Corasaniti M.T., Maccarrone M., Nistico R., Malorni W., Rotiroti D., Bagetta G. Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo. J. Neurochem. 2001, 79:1-8.
23. Corasaniti M.T., Nistico R., Costa A., Rotiroti D., Bagetta G. The HIV-1 envelope protein, gp120, causes neuronal apoptosis in the neocortex of the adult rat: a useful experimental model to study NeuroAIDS. Funct. Neurol. 2001, 16:31-38.
24. Corasaniti M.T., Piccirilli S., Paoletti A., Nistico R., Stringaro A., Malorni W., Finazzi-Agro A., Bagetta G. Evidence that the HIV-1 coat protein gp120 causes neuronal apoptosis in the neocortex of rat via a mechanism involving CXCR4 chemokine receptor. Neurosci. Lett. 2001, 312:67-70.
25. Del Valle L., Croul S., Morgello S., Amini S., Rappaport J., Khalili K. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J. Neurovirol. 2000, 6:221-228.
26. Desplats P., Dumaop W., Smith D., Adame A., Everall I., Letendre S., Ellis R., Cherner M., Grant I., Masliah E. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013, 80:1415-1423.
27. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993, 7:75-83.
28. di Rocco A., Bottiglieri T., Dorfman D., Werner P., Morrison C., Simpson D. Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin. Neuropharmacol. 2000, 23:190-194.
29. El-Hage N., Bruce-Keller A.J., Knapp P.E., Hauser K.F. CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice. J. Neuroimmune Pharmacol. 2008, 3:275-285.
30. El-Hage N., Wu G., Wang J., Ambati J., Knapp P.E., Reed J.L., Bruce-Keller A.J., Hauser K.F. HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 2006, 53:132-146.
31. Ellis R., Langford D., Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat. Rev. Neurosci. 2007, 8:33-44.
32. Ensoli F., Fiorelli V., DeCristofaro M., Santini Muratori D., Novi A., Vannelli B., Thiele C.J., Luzi G., Aiuti F. Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. J. Immunol. 1999, 162:6268-6277.
33. Everall I.P., Heaton R.K., Marcotte T.D., Ellis R.J., McCutchan J.A., Atkinson J.H., Grant I., Mallory M., Masliah E. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol. 1999, 9:209-217. HNRC Group.
34. Ferris M.J., Frederick-Duus D., Fadel J., Mactutus C.F., Booze R.M. The human immunodeficiency virus-1-associated protein, Tat(1-86), impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 2009, 159:1292-1299.
35. Fitting S., Booze R.M., Hasselrot U., Mactutus C.F. Differential long-term neurotoxicity of HIV-1 proteins in the rat hippocampal formation: a design-based stereological study. Hippocampus 2008, 18:135-147.
36. Fitting S., Booze R.M., Hasselrot U., Mactutus C.F. Dose-dependent long-term effects of Tat in the rat hippocampal formation: a design-based stereological study. Hippocampus 2010, 20:469-480.
37. Fitting S., Booze R.M., Mactutus C.F. Neonatal hippocampal Tat injections: developmental effects on prepulse inhibition (PPI) of the auditory startle response. Int. J. Dev. Neurosci. 2006, 24:275-283.
38. Fitting S., Booze R.M., Mactutus C.F. Neonatal intrahippocampal glycoprotein 120 injection: the role of dopaminergic alterations in prepulse inhibition in adult rats. J. Pharmacol. Exp. Ther. 2006, 318:1352-1358.
39. Fitting S., Booze R.M., Mactutus C.F. Neonatal intrahippocampal gp120 injection: an examination early in development. Neurotoxicology 2007, 28:101-107.
40. Fitting S., Booze R.M., Mactutus C.F. Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measures. Brain Res. 2008, 1232:139-154.
41. Fitting S., Ignatowska-Jankowska B.M., Bull C., Skoff R.P., Lichtman A.H., Wise L.E., et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol. Psychiatry 2013, 73:443-453.
42. Fitting S., Xu R., Bull C., Buch S.K., El-Hage N., Nath A., Knapp P.E., Hauser K.F. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am. J. Pathol. 2010, 177(3):1397-1410.
43. Foster S.B., Lu M., Glaze D.G., Reuben J.M., Harris L.L., Cohen E.N., et al. Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection. Clin. Immunol. 2012, 144:13-23.
44. Frankel A.D., Biancalana S., Hudson D. Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7397-7401.
45. Gartner S., Liu Y. Insights into the role of immune activation in HIV neuropathogenesis. J. Neurovol. 2002, 8:69-75.
46. Gary D.S., Milhavet O., Camandola S., Mattson M.P. Essential role for integrin linked kinase in Akt-mediated integrin survival signaling in hippocampal neurons. J. Neurochem. 2003, 84:878-890.
47. Gavin P., Yogev R. Central nervous system abnormalities in pediatric human immunodeficiency virus infection. Pediatr. Neurosurg. 1999, 31:115-123.
48. Gelman B.B., Nguyen T.P. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J. Neuroimmune Pharmacol. 2010, 5:92-102.
49. Glass J.D., Wesselingh S.L., Selnes O.A., McArthur J.C. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 1993, 43:2230-2237.
50. Gorantla S., Gendelman H.E., Poluektova L.Y. Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?. J. Neuroimmune Pharmacol. 2012, 7:352-362.
51. Grassi S., Dieni C., Frondaroli A., Pettorossi V.E. Influence of visual experience on developmental shift from long-term depression to long-term potentiation in the rat medial vestibular nuclei. J. Physiol. 2004, 560:767-777.
52. Greenhouse S.W., Geisser S. On methods in the analysis of profile data. Psychometrika 1959, 24:95-112.
53. Gupta S., Shah D.M., Shah I. Neurological disorders in HIV-infected children in India. Ann. Trop. Paediatr. 2009, 29:177-181.
54. Heinen K., Bosman L.W., Spijker S., van Pelt J., Smit A.B., Voorn P., Baker R.E., Brussaard A.B. GABAA receptor maturation in relation to eye opening in the rat visual cortex. Neuroscience 2004, 124:161-171.
55. Heyser C.J., Masliah E., Samini A., Campbell I.L., Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice overexpressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1500-1505.
56. Hooks M.S., Covin A.C., Juncos J.L., Justice J.B. Individual differences in basal and cocaine-stimulated extracellular dopamine in the nucleus accumbens using quantitative microdialysis. Brain Res. 1992, 587:306-312.
57. Hooks M.S., Juncos J.L., Justice J.B., Meiergerd S.M., Povlock S.L., Schenk J.O., Kalivas P.W. Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs. J. Neurosci. 1994, 14:6144-6152.
58. Jeang K.T. Human retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences 1996, III-3-III-18. Los Alamos National Laboratory, Los Alamos, NM.
59. Jeang K.T., Xial H., Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription. Tat. J. Biol. Chem. 1999, 274:28837-28840.
60. Jeremy R.J., Kim S., Nozyce M., Nachman S., McIntosh K., Pelton S.I., et al. Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams, Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics 2005, 115:380-387.
61. Jin C.Z., Zhao Y., Zhang F.J., Yao H.P., Wu L.J., Zhao H.X., Wei H.S., Wu N.P. Different plasma levels of interleukins and chemokines: comparison between children and adults with AIDS in China. Chin. Med. J. (Engl.) 2009, 122:530-535.
62. Jones M.V., Bell J.E., Nath A. Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 2000, 14:2709-2713.
63. Kang Y.J., Digicaylioglu M., Russo R., Kaul M., Achim C.L., Fletcher L., Masliah E., Lipton S.A. Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann. Neurol. 2010, 68:342-352.
64. Katz L.C., Shatz C.J. Synaptic activity and the construction of cortical circuits. Science 1996, 274:1133-1138.
65. Keller M.A., Venkatraman T.N., Thomas A., Deveikis A., LoPresti C., Hayes J., et al. Altered neurometabolite development in HIV-infected children: correlation with neuropsychological tests. Neurology 2004, 62:1810-1817.
66. Ketlinskii S.A., Kalinina N.M., Tsvetkova S.N., Rakhmanova A.G., Maslov V.N., Khaldeeva N.A. Tumor necrosis factor-alpha and interleukin-1beta in the blood plasma of patients with HIV infection. Vestn. Ross. Akad. Med. Nauk 1992, 36-41.
67. Kumar A.M., Ownby R.L., Waldrop-Valverde D., Fernandez B., Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J. Neurovirol. 2011, 17:26-40.
68. Le Doare K., Bland R., Newell M.L. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics 2012, 130:1326-1344.
69. Lipton S.A., Brenneman D.E., Silverstein F.S., Masliah E., Mucke L. gp120 and neurotoxicity in vivo. Trends Pharmacol. Sci. 1995, 16:122.
70. Ma M., Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J. Virol. 1997, 71:2495-2499.
71. Masliah E., Heaton R.K., Marcotte T.D., Ellis R.J., Wiley C.A., Mallory M., et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders, HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol. 1997, 42:963-972.
72. Midde N.M., Huang X., Gomez A.M., Booze R.M., Zhan C.G., Zhu J. Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. J. Neuroimmune Pharmacol. 2013, 8:975-987.
73. Mintz M. Clinical comparison of adult and pediatric NeuroAIDS. Adv. Neuroimmunol. 1994, 4:207-221.
74. Miura Y., Misawa N., Kawano Y., Okada H., Inagaki Y., Yamamoto N., et al. Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(5):2777-2782.
75. Moore D.J., Masliah E., Rippeth J.D., Gonzalez R., Carey C.L., Cherner M. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006, 20:879-887. HNRC Group.
76. Motz B.A., Alberts J.R. The validity and utility of geotaxis in young rodents. Neurotoxicol. Teratol. 2005, 27:529-533.
77. Murase S., Owens D.F., McKay R.D. In the newborn hippocampus, neurotrophin-dependent survival requires spontaneous activity and integrin signaling. J. Neurosci. 2011, 31:7791-7800.
78. Nath A., Anderson C., Jones M., Maragos W., Booze R., Mactutus C., Bell J., Hauser K.F., Mattson M. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J. Psychopharmacol. 2000, 14:222-227.
79. Nath A., Conant K., Chen P., Scott C., Major E.O. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J. Biol. Chem. 1999, 274:17098-17102.
80. Paramesparan Y., Garvey L.J., Ashby J., Foster C.J., Fidler S., Winston A. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J. Acquir. Immune Defic. Syndr. 2010, 55:134-136.
81. Parisi T., Ison J.R. Development of the acoustic startle response in the rat: ontogenetic changes in the magnitude of inhibition by prepulse stimulation. Dev. Psychobiol. 1979, 12:219-230.
82. Patel K., Hernan M.A., Williams P.L., Seeger J.D., McIntosh K., Dyke R.B., Seage G.R. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin. Infect. Dis. 2008, 46:1751-1760. Pediatric AIDS Clinical Trials Group 219/219C Study Team.
83. Patel K., Ming X., Williams P.L., Robertson K.R., Oleske J.M., Seage G.R. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009, 23:1893-1901.
84. Perrella O., Carrieri P.B., Guarnaccia D., Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. J. Neurol. 1992, 239:387-388.
85. Philippon V., Vellutini C., Gambarelli D., Harkiss G., Arbuthnott G., Metzger D., Roubin R., Filippi P. The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: involvement of cytokines. Virology 1994, 205:519-529.
86. Pocernich C.B., Sultana R., Mohmmad-Abdul H., Nath A., Butterfield D.A. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res. Brain Res. Rev. 2005, 50:14-26.
87. Romani B., Engelbrecht S., Glashoff R.H. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J. Gen. Virol. 2010, 91:1-12.
88. Roscoe R.F., Mactutus C.F., Booze R.M. HIV-1 transgenic female rat: synaptodendritic alterations of medium spiny neurons in the nucleus accumbens. J. Neuroimmune Pharmacol. 2014, [Epub ahead of print].
89. Sa M.J., Madeira M.D., Ruela C., Volk B., Mota-Miranda A., Paula-Barbosa M.M. Dendritic changes in the hippocampal formation of AIDS patients: a quantitative Golgi study. Acta Neuropathol. 2004, 107:97-110.
90. Saito Y., Sharer L.R., Epstein L.G., Michaels J., Mintz M., Louder M., Golding K., Cvetkovich T.A., Blumberg B.M. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 1994, 44:474-481.
91. Silvers J.M., Aksenova M.V., Aksenov M.Y., Mactutus C.F., Booze R.M. Neurotoxicity of HIV-1 tat protein: involvement of D1 dopamine receptor. Neurotoxicology 2007, 28:1184-1190.
92. Smith S.M., Pentlicky S., Klase Z., Singh M., Neuveut C., Lu C.Y., Reitz M.S., Yarchoan R., Marx P.A., Jeang K.T. An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J. Biol. Chem. 2003, 278:44816-44825.
93. Suksomboon N., Poolsup N., Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J. Clin. Pharm. Ther. 2007, 32:293-311.
94. Toggas S.M., Masliah E., Rockenstein E.M., Rall G.F., Abraham C.R., Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994, 367:188-193.
95. Tohmi M., Tsuda N., Watanabe Y., Kakita A., Nawa H. Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neurosci. Res. 2004, 50:67-75.
96. Tornatore C., Chandra R., Berger J.R., Major E.O. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 1994, 44:481-487.
97. Torre D., Ferrario G., Speranza F., Martegani R., Zeroli C. Increased levels of nitrite in the sera of children infected with human immunodeficiency virus type 1. Clin. Infect. Dis. 1996, 22:650-653.
98. UNAIDS (2013). 2013 UNAIDS Report on the global AIDS epidemic. Last accessed May 30 2014. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.
99. Vallat A.V., De Girolami U., He J., Mhashilkar A., Marasco W., Shi B., et al. Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS. Am. J. Pathol. 1998, 152:167-178.
100. Volmink J., Siegfried N.L., van der Merwe L., Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst. Rev. 2007, CD003510.
101. Wakselman S., Bechade C., Roumier A., Bernard D., Triller A., Bessis A. Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J. Neurosci. 2008, 28:8138-8143.
102. Wallace D.R., Dodson S., Nath A., Booze R.M. Estrogen attenuates gp120-and tat(1-72)-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 2006, 59:51-60.
103. Walton K.D., Harding S., Anschel D., Harris Y.T., Llinas R. The effects of microgravity on the development of surface righting in rats. J. Physiol. 2005, 565:593-608.
104. Wang G.J., Chang L., Volkow N.D., Telang F., Logan J., Ernst T., Fowler J.S. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 2004, 127:2452-2458.
105. Watson K., Edwards R.J. HIV-1 trans-activating (Tat) protein. Biochem. Pharmacol. 1999, 58:1521-1528.
106. Wiley C.A., Soontornniyomkij V., Radhakrishnan L., Masliah E., Mellors J., Hermann S.A., Dailey P., Achim C.L. Distribution of brain HIV load in AIDS. Brain Pathol. 1998, 8:277-284.
107. Willen E.J. Neurocognitive outcomes in pediatric HIV. Ment. Retard. Dev. Disabil. Res. Rev. 2006, 12:223-228.
108. Winer B.J. Statistical Principles in Experimental Design 1971, McGraw-Hill, New York. 2nd ed.
109. Yadav A., Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune Pharmacol. 2009, 4:430-447.
110. Zhu J., Ananthan S., Mactutus C.F., Booze R.M. Recombinant human immunodeficiency virus-1 transactivator of transcription(1-86) allosterically modulates dopamine transporter activity. Synapse 2011, 65:1251-1254.
111. Zhu J., Bardo M.T., Bruntz R.C., Stairs D.J., Dwoskin L.P. Individual differences in response to novelty predict prefrontal cortex dopamine transporter function and cell surface expression. Eur. J. Neurosci. 2007, 26:717-728.
112. Zhu J., Mactutus C.F., Wallace D.R., Booze R.M. HIV-1 tat protein-induced rapid and reversible decrease in [H-3]dopamine uptake: dissociation of [H-3]dopamine uptake and [H-3]2 beta-carbomethoxy-3-beta-(4-fluorophenyl) tropane (WIN 35,428) binding in rat striatal synaptosomes. J. Pharmacol. Exp. Ther. 2009, 329:1071-1083.